C. difficile is an emerging hospital-acquired infectious disease that affects individuals undergoing antibiotic treatment; the alteration of gut microbiota by antibiotics puts one at risk for colonization and disease. C. difficile disease (CDI) is mediated by toxins, and although anti-toxin antibodies have been targeted for vaccine development, such vaccines do not prevent bacterial colonization. Consequently, anti-toxin vaccines still allow the spread of infective spores into the environment. My goal is to identify antibodies and their target antigens that can prevent adhesion of C. difficile to the gut epithelium. These antibodies should prevent colonization and spread of disease. I am developing antibodies against various surface proteins of C. difficile and determining if they can inhibit adherence to colon epithelial cells in vitro. Finding a combination of antigens that can inhibit adherence should give us leads on how to formulate a vaccine that can prevent colonization and spread of C. difficile.